Clinical Trial Update: Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Dexrazoxane as a cardioprotective agent in anthracycline-treated breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DEXRAZOXANE (DEXRAZOXANE)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED